Funding round
Colossal Series C
Colossal, which works in genome editing and de-extinction services in Austin, raised $200M in a Series C round announced on 17 Jan 2025, led by TWG Global, at a $10.20B post-money valuation. 1 firm took part. It is Colossal's fourth venture round on record; the one before was a Series B in Jan 2023.
$200M
Amount raised
$10.20B
Post-money valuation
$10.00B pre-money
1
Investors
1 lead
2.0%
Stake sold
new money over the post-money
Valuation
What this round says about the price
This round priced Colossal at $10.20B after the new money. The $200M bought investors about 2.0% of the company. It came 24 months after Colossal's Series B. It is 47% of the $425M Colossal has raised in the venture rounds on record. No later venture round is on record for Colossal.
Colossal's funding rounds
Colossal has 4 venture rounds on record and 1 other deal. This one is highlighted.
- Seed 1 May 2021, led by Thomas Tull $15M
- Series A 9 Mar 2022, led by At One Ventures $60M
- Grant not a venture round 1 Oct 2022 amount not disclosed
- Series B 31 Jan 2023, led by United States Innovative Technology and Breyer Capital $150M
- Series C this round 17 Jan 2025, led by TWG Global $200M$10.20B post-money
Investors
Who put money in
TWG Global led the round.
Lead investor
- backs 4 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to hiring, product development, geographic expansion, scaling operations and working capital.
- Hiring
- Product development
- Geographic expansion
- Scaling operations
- Working capital
Comparable rounds
How it compares
38 Series C rounds in Biotechnology within a year either side disclosed an amount; the median was $55M, and this round was 3.6 times the median. The closest in time, other companies' Series C rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 7 Jan 2025 | $208M | not disclosed | Omega Funds and TCG Crossover |
| Biotechnology | 15 Jan 2025 | $92M | not disclosed | Nextech Invest |
| Biotechnology | 9 Jan 2025 | $55M | not disclosed | Cormorant Asset Management and Forbion |
| Biotechnology | 24 Dec 2024 | $15M | not disclosed | not named |
| Enveda Biotechnology | 21 Nov 2024 | $130M | not disclosed | Kinnevik and FPV Ventures |
| Biotechnology | 18 Mar 2025 | $74M | not disclosed | ARCH Venture Partners and TCG Crossover |
| Biotechnology | 26 Nov 2024 | $53M | not disclosed | Frazier Life Sciences |
| Biotechnology | 2 Apr 2025 | $150M | not disclosed | Bain Capital |
Sources
Where this comes from
Reported by 5 sources.
Questions
Frequently asked
How much did Colossal raise in its Series C round?
Colossal raised $200M in its Series C round, announced in Jan 2025.
Who led Colossal's Series C round?
TWG Global led it.
What was Colossal's valuation at the Series C round?
$10.20B post-money ($10.00B pre-money).
How does it compare with other Series C rounds in Biotechnology?
38 Series C rounds in Biotechnology within a year either side disclosed an amount; the median was $55M, and this round was 3.6 times the median.